| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics |
| Active, not recruiting | 3 | 420 | Europe, Canada, US | AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection | Summit Therapeutics, Akeso | Non-Squamous Non-small Cell Lung Cancer | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 398 | RoW | AK112, Pembrolizumab | Akeso | Advanced Non-small-cell Lung Cancer | 06/24 | 06/25 | | |
NCT06601335: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Not yet recruiting | 3 | 510 | RoW | AK117 in combination with AK112, Placebo in combination with Pembrolizumab | Akeso | Head and Neck Squamous Cell Carcinoma | 01/27 | 10/27 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
| Recruiting | 3 | 396 | RoW | AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel | Akeso | Advanced Squamous Non Small Cell Lung Cancer | 12/24 | 12/25 | | |
| Active, not recruiting | 3 | 322 | RoW | Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection | Akeso, Akeso | Non-Squamous Non-small Cell Lung Cancer | 06/24 | 11/25 | | |
HARMONi-3, NCT05899608: Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients |
|
|
| Recruiting | 3 | 400 | Canada, US | Ivonescimab Injection, Pembrolizumab Injection | Summit Therapeutics | Non-Small Cell Lung Cancer | 09/27 | 12/27 | | |
